List of Excipients in Branded Drug INTRAROSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AMAG Pharmaceuticals Inc	INTRAROSA	prasterone	64011-601	HYDROGENATED COCO-GLYCERIDES	2028-08-07
Millicent US Inc	INTRAROSA	prasterone	72495-501	HYDROGENATED COCO-GLYCERIDES	2028-08-07

Intrarosa Excipient Strategy and Commercial Opportunities for Prasterone Vaginal Inserts

Last updated: September 24, 2026

Intrarosa is a 6.5 mg prasterone vaginal insert approved by the FDA for moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. Its commercial differentiation depends on local delivery, low systemic exposure, patient convenience, and reliable vaginal retention. The current hard-fat insert creates opportunities for improved excipient systems, generic or 505(b)(2) development, combination packaging, and differentiated administration devices. The strongest commercial opportunities are improved leakage control, reduced insertion burden, longer storage stability, and lower-cost manufacturing without changing the approved dose or route.

What is Intrarosa and how does its dosage form work?

Intrarosa contains 6.5 mg of prasterone, also known as dehydroepiandrosterone or DHEA. It is administered intravaginally once daily at bedtime. The product is a solid vaginal insert formulated in a hard-fat base that melts or softens after placement and releases prasterone locally. The insert is supplied with a vaginal applicator. [1]

Prasterone is converted in vaginal tissues into androgenic and estrogenic metabolites. The product label describes local effects on vaginal tissues without positioning Intrarosa as systemic menopausal hormone therapy. The label reports low systemic exposure relative to circulating concentrations associated with systemic hormone treatment. [1]

Product attribute	Intrarosa profile
Active ingredient	Prasterone, 6.5 mg
Route	Vaginal
Dosage form	Vaginal insert
Administration	One insert nightly
Indication	Moderate-to-severe dyspareunia due to vulvar and vaginal atrophy associated with menopause
Applicator	Supplied for insertion
Key formulation issue	Release from a fatty, temperature-sensitive vaginal base
FDA application	NDA 208470
Approval date	November 17, 2016
Primary commercial constraint	Adherence, leakage, insertion convenience, and reimbursement

What excipients are used in Intrarosa?

The FDA prescribing information identifies hard fat as the inactive ingredient in the vaginal insert. The insert is not an aqueous gel, cream, tablet, or ring. Its excipient system is therefore central to product performance. [1]

Hard fat is a semi-solid lipid excipient used in suppositories and vaginal dosage forms. Relevant properties include:

• Melting behavior near physiological temperature
• Polymorphic stability
• Compatibility with prasterone
• Resistance to rancidity and oxidation
• Mechanical strength during packaging and insertion
• Controlled softening after vaginal administration
• Limited water uptake and predictable release

The product’s excipient simplicity supports manufacturing and may reduce formulation risk. It also creates potential design-around and improvement opportunities. A competing product does not necessarily need to reproduce the same hard-fat grade or manufacturing process if it can demonstrate pharmaceutical equivalence, bioequivalence, or an appropriate alternative clinical bridge.

What formulation attributes matter most?

The primary formulation targets are:

1. Retention: The insert should remain at the site of administration and limit leakage.
2. Dose uniformity: Each insert must deliver a consistent 6.5 mg dose.
3. Mechanical integrity: The unit should resist cracking, deformation, and sticking during handling.
4. Thermal performance: The base should remain stable during shipping and storage but soften after administration.
5. Chemical stability: Prasterone must remain within specification through the labeled shelf life.
6. Patient acceptability: The insert should minimize discharge, odor, discomfort, and applicator complexity.

Excipient selection should be evaluated through melting-point distribution, polymorphic form, particle size, mixing conditions, fill weight, cooling profile, and packaging interaction. Small changes in hard-fat grade or processing temperature can affect dissolution, release, and physical stability.

What excipient strategies could improve Intrarosa?

1. Hard-fat optimization

The lowest-risk strategy is to optimize the existing lipid platform. Candidate changes include:

• Alternative hard-fat grades with narrower melting ranges
• Blended lipid systems that improve release consistency
• Lower-viscosity melts to improve manufacturing throughput
• Higher mechanical strength to reduce breakage
• Reduced surface oiling during storage
• Improved resistance to temperature excursions

This approach may preserve the insert’s basic product concept while improving yield and shelf life. It is most attractive for a generic or authorized-generic program seeking pharmaceutical equivalence.

2. Bioadhesive excipients

A mucoadhesive polymer may increase vaginal residence time and reduce leakage. Potential materials include polycarbophil, carbomers, cellulose derivatives, alginates, and selected thiolated polymers. The principal risk is that a bioadhesive system may alter local exposure, irritation, removal, or patient acceptability.

A mucoadhesive product could support a differentiated 505(b)(2) strategy if it demonstrates a clinically meaningful administration advantage. It could also create new method-of-use and formulation claims, although those claims would require support from clinical and pharmacokinetic data.

3. Hydrophilic or lipid-hybrid inserts

A hybrid insert could combine a lipid carrier with a hydrophilic polymer phase. Such a system may offer more predictable hydration and release than a wholly fatty base. The development burden would be higher because the release mechanism, physical structure, and local tolerability would differ from Intrarosa.

Potential advantages include:

• Lower leakage
• More consistent release across vaginal pH conditions
• Better dose uniformity
• Greater flexibility in insert geometry
• Compatibility with lower-cost continuous manufacturing

The principal risks are moisture sensitivity, swelling, friability, and altered local metabolite exposure.

4. Controlled-release systems

A controlled-release insert could reduce administration frequency from daily dosing to several times per week or weekly dosing. This would have the clearest commercial differentiation but also the highest regulatory and clinical burden.

A longer-acting system may use:

• A multilayer insert
• A matrix with a diffusion barrier
• A biodegradable polymer
• A vaginal ring or ring-like device
• A reservoir system

A reduced-frequency claim would likely require clinical evidence showing comparable efficacy, acceptable local safety, and improved adherence. It would not be a routine excipient substitution.

5. Antioxidant and packaging systems

Prasterone and lipid excipients should be assessed for oxidation under heat, light, and oxygen exposure. A formulation developer may evaluate antioxidant systems, nitrogen flushing, low-oxygen blister packaging, and improved moisture-barrier materials.

Packaging can be commercially important even without changing the approved excipient composition. Individual unit-dose blisters may improve hygiene, portability, and dose tracking. A child-resistant secondary package may support retail distribution.

Any antioxidant or stabilizer must be evaluated for vaginal tolerability, extractables and leachables, impurity formation, and compatibility with the hard-fat matrix. The FDA label identifies hard fat as the inactive ingredient, so a new excipient or materially different excipient system may create a larger regulatory bridge than a packaging-only change. [1]

What commercial opportunities exist for Intrarosa formulation developers?

Generic Intrarosa

A generic developer could pursue an ANDA based on the reference product. The core opportunity is a lower-cost insert with pharmaceutical equivalence and acceptable bioequivalence or other FDA-supported equivalence evidence.

Important development targets include:

• Equivalent strength and dosage form
• Equivalent route of administration
• Comparable release behavior
• Comparable insert dimensions and administration method
• Equivalent or suitably justified inactive ingredients
• Stable commercial-scale manufacturing
• Competitive unit economics

Vaginal products can present more complex equivalence questions than conventional oral solids. Local action, limited systemic exposure, and the role of the dosage form may require careful use of comparative in vitro release, pharmacokinetic, clinical, or other equivalence studies.

505(b)(2) products

A 505(b)(2) application could support a modified prasterone product with:

• Reduced dosing frequency
• A new applicator
• A different insert size
• Improved retention
• A new vaginal delivery device
• A modified release profile
• A different packaging configuration
• A combination with a local comfort or moisturizing component, subject to regulatory classification

A 505(b)(2) program has greater differentiation potential than a conventional ANDA but carries clinical, regulatory, and patent risks. The product must establish that the change provides a meaningful benefit or a sufficiently supported alternative to the reference product.

Device-enabled commercial products

The applicator is a direct commercial opportunity. An improved device could address patient concerns about:

• Insertion depth
• Applicator cleanliness
• Single-use disposal
• Grip and control
• Packaging size
• Use by patients with limited dexterity

A reusable applicator could reduce waste but would add cleaning, contamination, and human-factors requirements. A preloaded, compact, single-use applicator may offer a simpler path to differentiation.

International licensing and regional commercialization

Prasterone vaginal products can support regional licensing where local menopause treatment markets have unmet demand or where vaginal hormone products are reimbursed differently from systemic hormone therapy.

Licensing value will depend on:

• Local regulatory classification
• Patent and supplementary protection rights
• Required clinical bridging
• Reimbursement status
• Distribution requirements
• Local manufacturing incentives
• Competition from estrogen creams, tablets, rings, moisturizers, and compounded products

The product’s non-estrogen positioning may be commercially relevant in markets where patients or prescribers seek alternatives to local estrogen therapy. Claims must remain within the approved regulatory label in each jurisdiction.

How strong is the Intrarosa patent and exclusivity position?

Intrarosa’s protection should be divided into four categories:

Protection category	Commercial relevance
Active-ingredient patents	Likely limited because prasterone is an established endogenous steroid
Method-of-use patents	May protect treatment of vulvovaginal atrophy or related symptoms
Formulation patents	May cover vaginal inserts, excipient systems, release characteristics, or manufacturing
Device and packaging rights	May protect applicators, presentation, or administration methods

The FDA Orange Book is the controlling source for patents listed against the approved NDA. Patent listings, expiration dates, pediatric exclusivity, and any later-listed patents should be checked against the current Orange Book record for NDA 208470. [2]

The FDA granted approval in 2016. Any regulatory exclusivity associated with the original approval is distinct from patent protection and does not by itself prevent later generic entry after its expiration. A generic applicant could submit a Paragraph IV certification against listed patents and trigger patent litigation if the NDA holder brings suit within the statutory period. [3]

What patent claims are most relevant to excipient developers?

The highest-value claim categories are likely to include:

• A vaginal insert containing prasterone at a defined concentration
• A hard-fat or lipid carrier
• A defined release profile
• A method of treating dyspareunia or vulvovaginal atrophy
• A specific dosage regimen
• A manufacturing process
• A particular applicator or administration system

A design-around program should vary more than the excipient name. It should assess formulation composition, concentration, geometry, manufacturing sequence, release mechanism, and use claims. A different hard-fat grade may not avoid a broader formulation claim.

What FDA regulatory pathway applies to an improved Intrarosa product?

The likely pathway depends on the degree of change.

Product change	Likely regulatory pathway
Same active, strength, route, and dosage form	ANDA, subject to equivalence requirements
New excipient with materially changed performance	ANDA or 505(b)(2), depending on equivalence
Reduced dosing frequency	505(b)(2) likely
New delivery device	505(b)(2), combination-product assessment, or device supplement
New indication	505(b)(2) or supplemental NDA
New formulation with clinical benefit	505(b)(2)
Packaging-only improvement	NDA supplement or relevant postapproval filing

The FDA will focus on local safety, impurity profile, content uniformity, dissolution or release, stability, microbial quality, applicator performance, and patient-use factors. Vaginal products also require attention to irritation, sensitization, microbiological effects, and compatibility with vaginal tissue.

How does Intrarosa compare with competing vaginal products?

Product class	Main advantage	Main limitation relative to Intrarosa
Vaginal estrogen cream	Flexible dosing and broad clinical familiarity	Messier administration and estrogen exposure
Vaginal estrogen tablet or insert	Small dose and established use	Requires repeated administration
Vaginal estrogen ring	Long duration	Device placement and removal
Vaginal moisturizers	Nonprescription access	Not equivalent to prescription hormonal treatment
Compounded DHEA products	Potential customization	Variable quality and regulatory oversight
Intrarosa	Local prasterone delivery and non-estrogen positioning	Daily insertion and possible leakage

Intrarosa’s most defensible commercial position is not simply the active ingredient. It is the combination of local prasterone delivery, a defined vaginal insert, a once-daily regimen, and a non-estrogen label position.

What generic launch risks exist?

The principal risks are:

• Patent litigation following a Paragraph IV filing
• Difficulty demonstrating equivalence for a locally acting vaginal product
• Inability to match release and retention behavior
• Manufacturing losses from lipid crystallization or thermal variability
• Patient rejection of leakage or applicator design
• Reimbursement pressure from lower-cost estrogen products
• Limited market expansion if physicians remain satisfied with established local estrogen therapies

A successful entrant should use a formulation platform that can support both an ANDA and a differentiated 505(b)(2) fallback. This creates optionality if an exact-equivalence program encounters technical or patent barriers.

Key Takeaways

• Intrarosa is a 6.5 mg prasterone vaginal insert formulated with hard fat and administered once daily.
• The main excipient opportunities are hard-fat optimization, mucoadhesion, controlled release, oxidation control, and improved packaging.
• A conventional generic program offers the lowest differentiation and regulatory risk but depends on demonstrating equivalence.
• A 505(b)(2) program could create greater value through reduced dosing frequency, improved retention, or a new applicator.
• The most commercially relevant patent issues concern formulation, method of use, manufacturing, and device claims.
• FDA Orange Book listings for NDA 208470 should control the assessment of listed patents and Paragraph IV exposure.
• A formulation developer should prioritize leakage reduction, thermal stability, patient convenience, and scalable lipid processing.

FAQs About Intrarosa Excipient and Commercial Strategy

Can a generic Intrarosa use a different hard-fat excipient?

Yes, if the product meets FDA equivalence requirements and the inactive-ingredient change is acceptable. A different hard-fat grade may affect release, stability, and local tolerability.

Could a weekly prasterone insert compete with Intrarosa?

Yes. A weekly insert would offer a clear adherence advantage, but it would likely require a 505(b)(2) pathway and clinical evidence supporting the modified exposure and dosing schedule.

Is Intrarosa an estrogen product?

No. Intrarosa contains prasterone, an endogenous steroid that is converted locally into estrogenic and androgenic metabolites. Its FDA-approved label identifies it as a prasterone vaginal insert.

Does a new applicator create a patentable opportunity?

Potentially. Patent value would depend on the applicator’s structure, loading mechanism, dose delivery, sterility or hygiene features, and method of use. Regulatory review would also assess human factors and compatibility with the insert.

What is the most attractive commercial formulation opportunity?

The strongest near-term opportunity is an improved insert that maintains the 6.5 mg dose while reducing leakage, improving thermal stability, simplifying insertion, and lowering manufacturing cost. A longer-acting product offers greater differentiation but requires substantially more regulatory and clinical investment.

References

1. U.S. Food and Drug Administration. (2023). Intrarosa (prasterone) vaginal insert, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin.
5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.
6. International Council for Harmonisation. (2009). ICH Q9: Quality risk management.